Survival Benefit of Primary Tumour Resection Compared to Systemic Therapy Alone in Stage IV Colorectal Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

480 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-01

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

About 20-25 percent of all colorectal cancer patients are diagnosed with International Union Against Cancer (UICC) stage IV disease. The benefit of primary tumor resection in the palliative context is therefore of high concern. However, empirical evidence from randomized and observational studies is inconsistent.

The objective of the present study is to compare the survival of palliative stage IV colorectal cancer patients selected for primary tumor resection and systemic treatment (PTR+SYST) to patients with systemic treatment only (SYST).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases

NCT05322486

Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms +10 more

UNKNOWN

A Retrospective Cohort Study Outcome of Treatment in Asymptomatic Stage 4 Colorectal Cancer

NCT04334395

Stage IV Colon Cancer

COMPLETED

Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients

NCT02149784

Colorectal Cancer Metastatic

UNKNOWN PHASE3

Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM

NCT06208371

Colorectal Neoplasms Malignant

RECRUITING PHASE3

Observation Versus Surgical Resection in Patients With Rectal Cancer Who Achieved Complete Clinical Response After Neoadjuvant Chemoradiotherapy

NCT02052921

Rectal Cancer

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Mortality after PTR+SYST compared to SYST alone was evaluated in a retrospective observational cohort of patients diagnosed from 2012-2020 in the cancer registry in the federal state of Brandenburg (Germany), excluding patients with rectal cancer of the lower two-thirds, emergency procedures, unknown Eastern Cooperative Oncology Group Score (ECOG) status, ECOG\>2, unknown metastatic status or unclear grading.

PTR was defined as resection of the primary tumor within 12 months after diagnosis (German procedure codes \[Operationen- und Prozedurencodes, OPS\] 5-455.\*, 5-456.\*, 5-484.\*, 5-485.\*). Cases with additional, but incomplete, resection of metastases were included. SYST was defined as the application of chemotherapy, antibody, or immunotherapy (alone or in combination) starting within 12 months after diagnosis.

The primary study endpoint was mortality. Survival of treatment groups (PTR+SYST vs. SYST) was compared using Kaplan-Meier survival plots and log-rank tests. Follow-up started at diagnosis and ended at death or December 31, 2020, whichever came first. Hazard ratios (HR) were calculated with multivariate Cox regression adjusting for sex (male, female), age at diagnosis (in years), ECOG status (0, 1, 2), localization and number of metastases according to TNM, 8th edition (M1a, M1b, M1c), grading (G1-2, G3-4), and localization of the primary tumor (colon carcinoma on the right side, colon carcinoma on the left side, or rectum carcinoma upper third).

Sensitivity analyses were performed to reduce indication bias. Propensity score matching was conducted based on a propensity score determined by logistic regression of treatment (PTR+SYST vs. SYST) on the same variables as above plus radiotherapy (yes/no). For each patient in the SYST group, a patient from the PTR+SYST group was randomly chosen with the same propensity score as the SYST patient, within a certain margin. The same analyses as above were performed on the matched patient groups. Delayed entry was used to account for the fact that patients who underwent PTR must survive from the date of diagnosis to the date of surgery to be included in the PTR+SYST group, whereas no such requirement was made for patients in the SYST group. Follow-ups started 3, 6, 9, and 12 months after diagnosis, excluding patients who died prior to this time irrespective of treatment (according to the "landmark" approach, as described by Alawadi et al., 2017).

Registry quality assurance measures and procedures:

Quality of German Clinical Cancer Registries have been analysed and described in detail by various publications (for example, PubMed-ID (PMID): 37568750; PMID: 28639952; PMID: 26474650; PMID: 25523845). In summary, the completeness and quality of the data can be rated as high to very high. The basis for this are the statutory reporting requirements, a high reporting fee by European standards for both the registries and the transmitting agent, regular quality conferences, highly standardised documentation requirements for the data transmission, specifications on register-related quality indicators (e.g. completeness), internal data validation measures and a secure and independent funding basis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Neoadjuvant Systemic Therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SYST

Systemic treatment only. Systemic treatment was defined as the application of chemotherapy, antibody, or immunotherapy (alone or in combination) starting within 12 months after diagnosis (definition for both groups)

Systemic Therapy

Intervention Type PROCEDURE

chemotherapy, antibody, or immunotherapy (alone or in combination) starting within 12 months after diagnosis

PTR+SYST

primary tumor resection and systemic treatment At least one of the following surgical procedures were performed: German procedure codes OPS 5-455.\*, 5-456.\*, 5-484.\*, 5-485.\*

Primary tumor resection

Intervention Type PROCEDURE

In addition to systemic therapy a primary tumor resection was performed.

Systemic Therapy

Intervention Type PROCEDURE

chemotherapy, antibody, or immunotherapy (alone or in combination) starting within 12 months after diagnosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Primary tumor resection

In addition to systemic therapy a primary tumor resection was performed.

Intervention Type PROCEDURE

Systemic Therapy

chemotherapy, antibody, or immunotherapy (alone or in combination) starting within 12 months after diagnosis

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosed colorectal carcinoma
* stage IV
* systemic therapy, starting within 12 months after diagnosis

Exclusion Criteria

* rectal cancer of the lower two-thirds
* emergency procedures
* unknown Eastern Cooperative Oncology Group (ECOG) performance status
* ECOG\>2
* unknown metastatic status
* unclear grading

Eligible Sex

ALL

Accepts Healthy Volunteers

No